- Home
- KPTI vs LFVN Comparison
KPTI vs LFVN Comparison
Compare KPTI & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- LFVN
- Stock Information
- Founded
- KPTI 2008
- LFVN N/A
- Country
- KPTI United States
- LFVN United States
- Employees
- KPTI N/A
- LFVN N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- LFVN Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- LFVN Health Care
- Exchange
- KPTI Nasdaq
- LFVN Nasdaq
- Market Cap
- KPTI 44.5M
- LFVN 145.2M
- IPO Year
- KPTI 2013
- LFVN N/A
- Fundamental
- Price
- KPTI $6.45
- LFVN $11.13
- Analyst Decision
- KPTI Buy
- LFVN Strong Buy
- Analyst Count
- KPTI 6
- LFVN 2
- Target Price
- KPTI $39.80
- LFVN $30.50
- AVG Volume (30 Days)
- KPTI 185.7K
- LFVN 161.9K
- Earning Date
- KPTI 11-04-2025
- LFVN 10-28-2025
- Dividend Yield
- KPTI N/A
- LFVN 1.62%
- EPS Growth
- KPTI N/A
- LFVN 226.09
- EPS
- KPTI N/A
- LFVN 0.75
- Revenue
- KPTI $137,269,000.00
- LFVN $228,530,000.00
- Revenue This Year
- KPTI $3.67
- LFVN $12.65
- Revenue Next Year
- KPTI $9.40
- LFVN $12.43
- P/E Ratio
- KPTI N/A
- LFVN $14.84
- Revenue Growth
- KPTI N/A
- LFVN 14.17
- 52 Week Low
- KPTI $3.51
- LFVN $9.00
- 52 Week High
- KPTI $16.95
- LFVN $27.38
- Technical
- Relative Strength Index (RSI)
- KPTI 54.78
- LFVN 36.56
- Support Level
- KPTI $5.70
- LFVN $10.30
- Resistance Level
- KPTI $6.89
- LFVN $12.10
- Average True Range (ATR)
- KPTI 0.59
- LFVN 0.96
- MACD
- KPTI -0.13
- LFVN -0.22
- Stochastic Oscillator
- KPTI 30.61
- LFVN 20.85
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.